Genomic Analysis of two NDM-1 *Providencia stuartii* Strains Recovered from a Single Patient

Amparo Hoard1 · Sabrina Montaña2 · Alessandro Moriano1 · Jennifer S. Fernandez1 · German M. Traglia2 · Cecilia Quiroga3 · Agustina Franchi4 · Emilia Cohen4 · Cecilia Corigliano4 · Marisa Almuzara4 · María Soledad Ramírez1

Received: 3 June 2020 / Accepted: 1 October 2020 / Published online: 13 October 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract

In the last years, an increasing number of untreatable infections caused by drug-resistant microbes have impacted the health care system. Worldwide, infections caused by carbapenem-resistant (CR) Gram-negative bacilli have dramatically increased. Among the CR-Gram-negative bacilli, those producing carbapenemases, such as NDM-1, are the main concern. Different *Enterobacterales* harboring NDM-1 have been reported lately. *Providencia stuartii*, a member of the *Morganellaceae* family, is ubiquitous in the environment, but is also known to cause nosocomial infections. Here we describe the genomic analysis of two NDM-1-producing *P. stuartii* strains recovered from the same patient as well as other carbapenem-resistant strains recovered from the same hospital. As a result of the genomic analysis thirteen resistance genes, including three to β-lactams (*bla*OXA-1, *bla*TEM-1, *bla*NDM-1), four to aminoglycosides (aphA6, aac(3)-IId, aac(2′)-Ia, aac(6′)-Ib-cr5), one to sulfonamides (*sul1*), two to chloramphenicol (*catB3, catA3*), one to rifampicin, one to bleomycin (*ble*), and one to tetracycline (*tet(B)*) were found. Moreover, a variety of mobile genetic elements, such as insertion sequences, plasmids and phage-related sequences, were found within *P. stuartii* genomes. The spread of carbapenem-resistant isolates remains a significant clinical and public health concern. Therefore, we considered that the detection of CR isolates is an essential step in addressing this problem.

Introduction

Carbapenem antibiotics are generally considered to be the last option in the treatment of patients with severe bacterial infections. The recent increase in the rates of carbapenem-resistant *Enterobacterales* (CRE) among healthcare-associated *Enterobacterales* is a major concern [1–3]. Under those circumstances, CRE infections are associated with high mortality due to limited treatment options [1, 3]. In addition, according to the CDC report Antibiotic Resistance Threats in the United States 2019, CRE was also found in the urgent threat category. Three groups of carbapenemases (KPC, NDM, and OXA-48) are currently considered to be the major β-lactamases with epidemiological and clinical significance [4, 5]. *Providencia* species are members of the *Morganellaceae* family, among them, *P. stuartii* and *P. rettgeri* are the most common causes of infections in hospitalized patients, mainly urinary tract infections [6, 7]. Moreover, cases of peritonitis, endocarditis, meningitis, bacteremia due to *P. stuartii* has been also reported [6, 8–11].

*P. stuartii* is intrinsically resistant to colistin and tigecycline, but carbapenem-resistant *P. stuartii* (CRPS) are
increasingly reported, mainly due to blanDM-1 [6, 12, 13]. Recently, Molnar et al. described the presence of 77 CRPS isolates, recovered from different hospitals in Romania, of which 67 were NDM-1 positive [14]. In addition, CRPS VIM and KPC positive strains were also described in the literature [15–19].

In the present study, we described the clinical data and the whole genome sequence (WGS) analysis of two NDM-1 CRPS strains from a 55-year-old patient with a history of chronic obstructive pulmonary disease, hypertension and diabetes. Moreover, we described the molecular characterization of two more CR isolates (Klebsiella pneumoniae and Pseudomonas aeruginosa) from the same patient together with others CR isolates (P. stuartii, P. rettgeri, Proteus mirabilis and K. pneumoniae) recovered from the same hospital.

**Materials and Methods**

**Clinical Case**

In April of 2018, the patient was admitted to the intensive care unit (ICU) due to cranial brain trauma requiring craniectomy with evacuation of the intracerebral hematoma plus surgical clipping of the sylvian aneurysm and placement of an external ventricular shunt. In June, the patient presented febrile registers associated with hypoventilation and fatigue, therefore blood cultures, catheter-drawn blood cultures and urine cultures were performed. K. pneumoniae (Kb846) grew in the two blood culture bottles and in the blood-culture drawn from the catheter. In addition, the growth of Providencia stuartii (Ps848) was obtained in one of two bottles of blood culture. In the urine culture, Pseudomonas aeruginosa (PaC850) and P. stuartii (Ps850) were isolated (Table 1). The established treatment was with fosfomycin, meropenem and amikacin.

| Table 1 General features of the clinical strains included in the study |
|---|---|---|---|
| Strain | Specie | Patient Source | Resistance profile* |
| | | | AMP; SAM; TZP; CEP; CTX; CAZ; IMP; MEM; AMK; GEN; NAL; CIP; NIT; COL; TMS | Rapid Blue-Carba test Metallo-β-lactamases KPC-MBL Kit |
| Kb846  | K. pneumoniae | 1 Blood culture, catheter | Positive | Negative | Positive |
| Ps848  | P. stuartii | 1 Blood culture | Positive | Positive | Positive |
| PaC850 | P. aeruginosa | 1 Urine culture | Positive | Positive | Positive |
| Ps850  | P. stuartii | 1 Urine culture | Positive | Positive | Positive |
| Ps722  | P. stuartii | 2 Abscess culture | (Indeterminate) | Positive | Positive |
| Pr783  | P. rettgeri | 3 Surgical toilette | (Indeterminate) | Positive | Positive |
| Pm856  | P. mirabilis | 4 Urine culture | Positive | Positive | Positive |
| Kb443  | K. pneumoniae | 5 Tracheal aspirate | Positive | Positive | Positive |

*Resistance profile only; Indeterminate: a color change was obtained after 2 h of incubation

AMP ampicillin, SAM ampicillin-sulbactam, TZP piperacillin-tazobactam, CEP cefotaxime, CTX cefotaxime, CAZ ceftazidime, IMP imipenem, MEM meropenem, AMK amikacin, GEN gentamycin, NAL nalidixic acid, CIP ciprofloxaxine, NIT nitrofurantoin, COL colistin, TMS trimethoprimsulfamethoxazole, FEP cephepine

© Springer
for 14 days. During treatment the patient evolved with increased blood sodium attributable to fosfomycin, so it was changed to tigecycline. With the exception of an oxygen requirement following a tracheostomy, the patient’s condition remained stable, steadily improving favorably without febrile records (Table 2).

Other Clinical CR Strains

At the same time, four other CR isolates were recovered. Two isolates were *P. stuartii* (Ps722) and *P. rettgeri* (Pr783), which were obtained from the surgery service. The other two isolates were a *Proteus mirabilis* isolate (Pm856) obtained from a urine culture of a dialyzed patient, and a *K. pneumoniae* isolate (Kb443) from a tracheal aspirate of a pediatric patient, were recovered (Table 1).

Antimicrobial Susceptibility Assay

The recovered isolates were characterized at species level by conventional biochemical tests and by the VITEK 2 System (bioMérieux). The susceptibility assay was performed using the VITEK 2 (AST-279 panel). The minimum inhibitory concentration (MIC) results were interpreted using the Clinical and Laboratory Standards Institute [20]. For the rapid detection of carbapenemases, a colorimetric method (Rapid Blue-Carba Test) was also performed [21]. A color change obtained after the reading limit time (120 min) was recorded as an indeterminate result. To study the presence of metallo-β-lactamases (MBL), a double-disc diffusion test using meropenem and imipenem (10 μg, OXOID, UK) was performed on Mueller Hinton agar using an 1900/750 μg EDTA/SMA disc (Laboratorios Britania, Argentina). Additionally, to detect the presence of serine or oxacillinase carbapenemases, the screening method using the KPC-MBL Kit Confirm ID Pack (Rosco Taastrup, Denmark) containing meropenem (10 μg), meropenem 10 μg + dipicolinic acid (Metallo-β-Lactamase inhibitor); meropenem 10 μg + cloxacillin (AmpC inhibitor); meropenem 10 μg + phenylboronic acid (KPC and AmpC inhibitor) was carried out [22].

General Molecular Techniques

To perform the molecular characterization of the isolates recovered, total DNA extraction was carried out using Wizard® Genomic DNA Purification Kit according to manufacturer instructions (Promega, Madison, WI). PCR reactions using GoTaq® enzyme (Promega, Madison, WI) were carried out for the most common carbapenemase genes (*bla*<sub>IMP</sub>, *bla*<sub>VIM</sub>, *bla*<sub>KPC</sub> and *bla*<sub>NDM</sub>), as well as, the presence of mobile elements related with them. Plasmid extractions were carried using two different techniques, the QIAPrep Spin Miniprep Kit following manufacturer instructions (Qiagen Germantown, MD, USA) and a manual plasmid extraction design for megaplasmids [23, 24].

Whole-genome Sequence and Sequences Analysis of Ps848 and Ps850 Clinical Isolates

Genomic DNA was extracted using a DNeasy Blood and Tissue kit from Qiagen (Qiagen Germantown, MD, USA). Whole-genome shotgun sequencing was performed using Illumina NextSeq550. De novo assembly was performed with SPAdes Assembler (version.3.1.0) [25] using a pre-assembly approach with Velvet [26]. The RAST (Rapid Annotation using Subsystem Technology) server was used to predict and annotate open reading frames [27], and BLAST (v.2.0) software was utilized to confirm the predictions. The Whole Genome Shotgun project has been deposited at GenBank under the accession JABLTB00000000 and JABLTC00000000 for Ps848 and Ps850, respectively. ARG-ANNOT [28] and The Resistance Gene Identifier (CARD-RGI) [29] were used to identify antibiotic resistance genes. The ISfinder and PHASTER ‘s softwares were used to identify insertion sequences and phages and prophages, respectively [30, 31]. The RaxML software was used to predict the phylogenetic relation among the strains [32].

Results

Antibiotic Susceptibility and Carbapenemase Identification in Carbapenem-Resistant Gram-Negative Strains

Antimicrobial susceptibility testing revealed that Ps848, Ps850 and Ps783 exhibited an extreme-drug resistant phenotype, where Ps850 and Ps783 were susceptible to amikacin and trimethoprim/sulfamethoxazole, and Ps848 was only susceptible to amikacin. Among Kb isolates, Kb443 was only susceptible to colistin and nitrofurantoin, while

| Features                        | Whole genome Ps848 | Ps850 |
|---------------------------------|--------------------|-------|
| Total number of base pairs      | 4,404,416          | 4,403,514 |
| G + C content (%)               | 41.2%              | 41.2% |
| Number of possible ORFs         | 4,379              | 4,382 |
| Number of insertion sequences   | 8                  | 8     |
| Number of resistance genes      | 13                 | 13    |

Table 2: General features of the Ps848 and Ps850 genomes
Kb846 was resistant to all of the antibiotic tested. PaC850 was multidrug resistant with susceptibility to amikacin, gentamicin and colistin. Moreover, Pm856 and Pr783 were both susceptible to amikacin and Pr783 was also susceptible to ciprofloxacin (Table 1).

The four isolates obtained from the same patient showed a positive result for the Rapid Blue-Carba test: a weak positive result (light green color) for Ps848, Ps850 and PaC850 isolates between 60 and 90 min of incubation and a strong positive result for isolate Kb846 at 30 min of incubation were obtained. Moreover, a positive result was also obtained for the isolates Pm856 and Kb443. Also, an indeterminate result was obtained for the isolates Ps722 and Pr783. In addition, synergy between carbapenems and EDTA was observed for Ps848, Ps850, PaC850, Pr783, Ps722, Pm856 and Kb443 isolates. Additionally, the KPC-MBL Kit Confirm ID Pack showed the presence of MBL-type carbapenemase in Ps848, Ps850, PaC850, Pr783, Ps722, Pm856, Kb846 and Kb443 isolates. A halo difference of ≥ 5 mm in the case of meropenem + dipicolinic acid with respect to the meropenem 10 μg disc was observed. Instead, for isolate Kb846, a halo difference of ≥ 5 mm in the case of meropenem + phenylboronic acid with respect to the meropenem 10 μg disc was observed (Table 1).

WGS of Ps848 and Ps850: Genome Features, Antibiotic Resistance Determinant, and Mobile Genetic Elements

The draft genome of Ps848 consists of 4,404,416 bp. The RAST server predicted 4382 protein-coding genes with a corresponding G + C content of 41.2%, whereas the draft genome of Ps850 consists of 4403,514 bp and the RAST server predicted 4382 protein-coding genes with a corresponding G + C content of 41.2% (Table 1).

Phylogenetic analysis was performed using RaxML and showed that both strains belong to the same clone (Fig. 1).

Using the ARG-ANNOT and CARD-RGI software’s analysis of the class 1 integron revealed the presence of four gene cassettes (aac(6′)-Ib-cr5, blaOXA-1, catB3, and arr3) within the variable region 1 (VR-1) (Fig. 2b). The 3′-CS conserved region containing qacEΔ1/sul1 genes was also present. In addition, the same class 1 integron array was present in PaC850. However, a different class 1 integron, containing aac(6′)-Ib-cr5 in the variable region, was found in Kp846. Ps848 and Ps850 strains also harbored a class 2 integron. The presence of Tn7 transposon related genes nsaA, nsaB, nsaC and nsaD were also found.

Regarding to the others the others CR isolates found in the same hospital, Pm856, Kb443, Ps722, Pr783 exposed the presence of blaNDM-1, blaTEM-1 gene was only found in Pm856 and Kb443. Moreover, a class 1 integron harboring the blaVIM-2 gene was found in Ps722, Ps856 and Kb443.

Discussion

In this work, we present the molecular characterization of two carbapenemase-producing P. stuartii and two more CR isolates (P. aeruginosa and K. pneumoniae) recovered from...
Fig. 1  Core-genome phylogeny of *P. stuartii* and *P. rettgerii*. Twenty *P. stuartii* genomes and eighteen *P. rettgerii* genomes was represented in the phylogenetic tree. *P. stuartii* and *P. rettgerii* available in GenBank database is indicate in red and blue, respectively. The isolates sequenced are indicate in black.

Fig. 2  a Genetic context of *bla*<sub>NDM-1</sub> gene found in Ps848 and Ps850. b Schematic representation of the class 1 integron found in Ps848 and Ps850
a single patient. We also performed the molecular characterization of other CR isolates, recovered from the same period of time in the hospital (P. stuartii, P. rettgeri, P. mirabilis and K. pneumoniae). The presence of more than one CR Enterobacteriales harboring plasmid-mediated NDM-1 in a single patient has been described in the literature [33, 34]. Recently, Abdallah et al. also described a case of hospital-acquired pneumonia due to CR P. stuartii and K. pneumoniae in a single patient [35]. Among Providencia’s members, P. stuartii and P. rettgeri are the most common causes of infections in hospitalized patients, and are mainly associated with urinary tract infections. It has been also described in nosocomial outbreaks caused by multidrug-resistant strains of P. stuartii [36–39]. In addition, P. stuartii clinical isolates harboring plasmids encoding different beta-lactamases have also been studied [12, 13, 40]. The WGS analysis of Ps850 and Ps848 exposed the presence of 13 resistance genes (blaOXA-1, blaTEM-1, blaNDM-1, aphA6, aac(3)-IId, aac(2’)-Ia and aac(6’)-Ib-cr, sul1, catB3, catA3, arr3, ble and tet(B)). These results are in accordance with previous reports that showed the presence of MDR P. stuartii clinical isolates [41–43]. Moreover, the presence of P. stuartii clinical isolates harboring blaNDM-1 gene was also described in the literature [12, 13, 35]. Among the other CR isolates analyzed Pm856, Kb443, Ps722 and Pr783 were also NDM-1 positive. Furthermore, in the literature the presence of the resistance, K. pneumoniae and P. rettgeri harboring blaNDM-1 gene was also reported [44–46]. Similarly, the blaNDM-1 gene with the same 3’ end region found in Ps850 and Ps848 was previously reported present in plasmids in E. coli 3426 (AN LS992188) and C. freundii CRE3 (AN MK101346). While the same context (upstream and downstream) was previously reported in A. nosocomialis IEC38057 (AN MK053934) and A. baumannii (AN LC032101).

In addition, a variety of MGEs were also identified in Ps850 and Ps848 genomes, such as a resistance plasmid, ISs, several phage-related regions and a CRISPR-Cas type I-F. The analysis of the plasmids identified in Ps850 and Ps848, showed that they share several traits with P. rettgeri plasmids p16-01,619–1 and pPrY2001. As a common feature, they all encode the beta-lactamase NDM-1. Martinez et al., proposed that all P. rettgeri NDM positive strains harbor a putative conjugative transfer mechanism named Tra-Pre, which is not present in pNDM-BJ01-like plasmids from Acinetobacter spp [47]. We hypothesized that this novel plasmid backbone could have emerged as the consequence of different recombination events (homologous and non-homologous) between coexisting plasmids in the clinical setting. Furthermore, a class 1 integron was also identified in both genomes. The same class 1 array was reported in K. pneumoniae WCHKP020030 (AN CP028791) and integrons with regions similar to VR-1 were also described in C. freundii AA535 and AA593 (AN MH594477 and MH594478, respectively). Only a few cases of a P. stuartii harboring class 1 integrons have been reported [16, 48]. In addition, the presence of the class 2 integron and the Tn7 transposon associated genes were also found in the analyzed genomes. Barlow et al., previously described the presence of the intI2 gene in P. stuartii isolates not associated with the typical class 2 integron array. They also suggested that the intI2 gene present in their isolates could be part of a novel super-integron structure; however, further analysis needs to be done to confirm [49]. The presence of P. stuartii harboring a class 2 integron was scarcely described in the literature [49, 50]. Regarding the other CR isolates PaC850, Kp846, Ps722, Pm856 and Kb443 harbored also class 1 integron. The spread of carbapenemase-producing isolates remains a significant clinical and public health concern. Therefore, we considered that the detection of carbapenemase production is an essential first step in combating this problem.

Acknowledgements Part of the authors’ work was supported by NIH S33GM125556 to MSR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. J.S.F. was supported by grant MHIRT 2T37MD001368 from the National Institute on Minority Health and Health Disparities, National Institute of Health. SM is recipient of a postdoctoral fellowship from CONICET. C.Q and G.M.T. are members of the CIC from CONICET.

Authors’ Contributions (1) Conception and design of the study: AH, SM, AM, JSF, GMT, CQ, MA, MSR; (2) Acquisition of data: AH, SM, AM, JSF, GMT, AF, EC, CC, MA, MSR; (3) Analysis of data: AH, SM, GMT, CQ, MSR; (4) Drafting and revision of manuscript: AH, SM, GMT, CQ, MA, MSR.

Compliance with Ethical Standards

Conflict of interest The authors have declared that they have no conflict of interest.

Ethical Standards All procedures performed in this study were in accordance with the ethical standards of the Hospital Eva Peron, Buenos Aires, Argentina, the 1964 Helsinki Declaration, its later amendments and the National Law on the protection of personal data No 25.326.

Informed Consent Informed consent was obtained from the patient involved in the study.

References

1. Durante-Mangoni E, Andini R, Zampino R (2019) Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect 25:943–950
2. Lutgring JD (2019) Carbapenem-resistant Enterobacteriaceae: An emerging bacterial threat. Semin Diagn Pathol 36:182–186
3. Yoo JH (2018) The Infinity War: How to Cope with Carbapenem-resistant Enterobacteriaceae. J Korean Med Sci 33:e255
4. Nordmann P, Naas T, Poirel L (2011) Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791–1798

5. Martinez-Martinez L (2019) Carbapenemases: The never-ending story. Enferm Infec Microbiol Clin 37:73–75

6. Abdallah M, Balshi A (2018) First literature review of carbapenem-resistant Providencia. New Microbes New Infect 25:16–23

7. Wenzel RP, Hunting KJ, Osterman CA, Sande MA (1976) Providencia stuartii, a hospital pathogen: potential factors for its emergence and transmission. Am J Epidemiol 104:170–180

8. Krake PR, Tandon N (2004) Infective endocarditis due to Providencia stuartii. South Med J 97:1022–1023

9. Sipahi OR, Bardak-Ozcem S, Ozgiray E, Aydemir S, Yurtseven T, Yamazhan T, Tasbakan M, Ulusoy S (2010) Meningitis due to Providencia stuartii. J Clin Microbiol 48:4667–4668

10. Unverdi S, Akay H, Ceri M, Inal S, Altay M, Demiroz AP, Duranay M (2011) Peritonitis due to Providencia stuartii. Perit Dial Int 31:216–217

11. Woods TD, Watanakunakorn C (1996) Bacteremia due to Providencia stuartii: review of 49 episodes. South Med J 89:221–224

12. Managerio V, Sampaio DA, Pereira P, Rodrigues P, Vieira L, Palos C, Canica M. 2015. Draft Genome Sequence of the First NDm-1-Producing Providencia stuartii Strain Isolated in Portugal. Genome Announc 3.

13. McGann P, Hang J, Clifford RJ, Yang Y, Kwak YI, Kuschner RA, Lesho EP, Waterman PE (2012) Complete sequence of a novel 178-kilobase plasmid carrying blaNDM-1 in a Providencia stuartii strain isolated in Afghanistan. Antimicrob Agents Chemother 56:1673–1679

14. Molnar S, Flonta MMM, Almas A, Buza M, Licker M, Rus M, Foldes A, Szekely E (2019) Dissemination of NDm-1 carbapenemase-producer Providencia stuartii strains in Romanian hospitals: a multicentre study. J Hosp Infect 103:165–169

15. Aires CAM, Almeida ACS, Vilela MA, Morais-Junior MA, Morais MMC (2016) Selection of KPC-2-producing Providencia stuartii strains from Brazilian hospitals: a multicentre study. J Hosp Infect 103:165–169

16. Douka E, Perivolioti E, Kraniotaki E, Fountoulis K, Economou F, Tsakris A, Skoutelis A, Routsi C (2015) Emergence of a KPC-2-producing Providencia stuartii strain isolated in Afghanistan. Antimicrob Agents Chemother 59:2447–2450

23. Montana S, Palombarani S, Carulla M, Kunst A, Rodriguez CH, Nastro M, Vay C, Ramirez MS, Almuzara M (2017) First case of bacteraemia due to Acinetobacter schindleri harbouring blaNDM-1 in an immunocompromised patient. New Microbes New Infect 21:28–30

24. Montana S, Schramm ST, Traglia GM, Chiem K, Parmeciano Di Noto G, Almuzara M, Barberis C, Vay C, Quiroga C, Tolmasy ME, Iriarte A, Ramirez MS (2016) The Genetic Analysis of an Acinetobacter johnsonii Clinical Strain Evidenced the Presence of Horizontal Genetic Transfer. PLoS ONE 11:e0161528

25. Bankевич A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prijibelski AD, Pyszkin AV, Sirotnik AV, Vyakhhi N, Tesler G, Alekseyev MA, Pevzner PA (2012) SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477

26. Zerbino DR, Birney E (2008) Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res 18:821–829

27. Aziz RK, Bartels D, Best AA, DeJongh M, Diz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LLK, Paarmann D, Piaczan T, Parrello B, Pusch GD, Reich C, Stevens R, Vassjea O, Vonstein V, Wilke A, Zagnitko O (2008) The RAST Server: rapid annotations using subsystems technology. BMC Genomics 9:75

28. Gupta SK, Padmanabhan BR, Dieme SN, Lopez-Rojas R, Kempf M, Landraud L, Rolain J-M (2014) ARG-ANNOT, a New Bioinformatic Tool To Discover Antibiotic Resistance Genes in Bacterial Genomes. Antimicrob Agents Chemotherapy 58:212–220

29. Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, Lago BA, Dave BM, Pereira S, Sharma AN, Doshi S, Courtor M, Lo R, Williams LE, Frye JG, Elsayegh T, Sardar D, Westman EL, Pawlowski AC, Johnson TA, Brinkman FS, Wright GD, McArthur AG (2017) CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res 45:D566–D573

30. Sigueri P, Perochon J, Lestrade L, Mahillon J, Chandler M (2006) ISfinder: the reference centre for bacterial insertion sequences. Nucleic Acids Res 34:D52–D56

31. Zhou Y, Liang Y, Lynch KH, Dennis JJ, Wishart DS (2011) PHAST: a fast phage search tool. Nucleic Acids Res 39:W347–W352

32. Stamatakis A (2014) RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30:1312–1313

33. Martino F, Tijet N, Melano R, Petroni A, Heinz E, De Belder D, Faccone D, Rapoport M, Biondi E, Rodrigo V, Vazquez M, Pasteran F, Thomson NR, Corso A, Gomez SA (2019) Isolation of five Enterobacteriaceae species harbouring blaNDM-1 and mcr-1 plasmids from a single paediatric patient. PLoS ONE 14:e0221960

34. Aires-de-Sousa M, Ortiz de la Rosa JM, Goncalves ML, Costa A, Nordmann P, Poirel L (2020) Occurrence of NDM-1-producing Morganella morganii and Proteus mirabilis in a single patient in Portugal: probable in vivo transfer by conjugation. J Antimicrob Chemother 75:903–906

35. Abdulhadi M, Alhabahi R, Alqudah N, Alldyatt B, Alharthy A (2018) First report of carbapenem-resistant Providencia stuartii in Saudi Arabia. New Microbes New Infect 26:107–109

36. Mao YC, Chang CL, Huang YC, Su LH, Lee CT (2018) Laboratory investigation of a suspected outbreak caused by Providencia stuartii with intermediate resistance to imipenem at a long-term care facility. J Microbiol Immunol Infect 51:214–219

37. Mfin B, Kiari S, Chaaari A, Medhioub F, Rhimi F, Bouaziz M, Hammami A (2013) Nosocomial dissemination of Providencia stuartii isolates carrying blaOXA-48, blaqbeta, blaqCMY-4 and qnrA6 in a Tunisian hospital. J Antimicrob Chemother 68:329–332
38. Saida NB, Thabet L, Messadi A, Bouselmi K, Turki A, Boukaida J (2008) Clonality of Providencia stuartii isolates involved in outbreak that occurred in a burn unit. Burns 34:829–834
39. Zavascki AP, Carvalhaes CG, da Silva GL, Tavares Soares SP, de Alcantara LR, Elias LS, Sandri AM, Gales AC (2012) Outbreak of carbapenem-resistant Providencia stuartii in an intensive care unit. Infect Control Hosp Epidemiol 33:627–630
40. Clifford RJ, Hang J, Riley MC, Onmus-Leone F, Kuschner RA, Lesho EP, Waterman PE (2012) Complete genome sequence of Providencia stuartii clinical isolate MRSN 2154. J Bacteriol 194:3736–3737
41. Liakopoulos A, Oikonomou O, Wareham DW. 2017. Draft Genome Sequence of Providencia stuartii PS71, a Multidrug-Resistant Strain Associated with Nosocomial Infections in Greece. Genome Announc 5.
42. Pillonetto M, Arend L, Vespero EC, Pelisson M, Chagas TP, Carvalho-Assef AP, Asensi MD (2014) First report of NDM-1-producing Acinetobacter baumannii sequence type 25 in Brazil. Antimicrob Agents Chemother 58:7592–7594
43. Tumbarello M, Citton R, Spanu T, Sanguinetti M, Romano L, Fadda G, Cauda R (2004) ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital. J Antimicrob Chemother 53:277–282
44. Polit L, Gartzonika K, Spanakis N, Zarkotou O, Poulou A, Skoura L, Vrioni G, Tsakris A (2019) Emergence of NDM-1-producing Klebsiella pneumoniae in Greece: evidence of a widespread clonal outbreak. J Antimicrob Chemother 74:2197–2202
45. Kanzari L, Ferjani S, Saidani M, Hamzraoui Z, Jendoubi A, Harbaoui S, Ferjani A, Rehaiem A, Boutiba Ben Boubaker I, Slim A (2018) First report of extensively-drug-resistant Proteus mirabilis isolate carrying plasmid-mediated blaoxy in a Tunisian intensive care unit. Int J Antimicrob Agents 52:906–909
46. Shin S, Jeong SH, Lee H, Hong JS, Park MJ, Song W (2018) Emergence of multidrug-resistant Providencia rettgeri isolates co-producing NDM-1 carbapenemase and PER-1 extended-spectrum beta-lactamase causing a first outbreak in Korea. Ann Clin Microbiol Antimicrob 17:20
47. Marquez-Ortiz RA, Haggerty L, Olarte N, Duarte C, Garzar Ramos U, Silva-Sanchez J, Castro BE, Sim EM, Beltran M, Mondaca MV, Valderrama A, Castellanos JE, Charles IG, Vanegas N, Escobar-Perez J, Petty NK (2017) Genomic Epidemiology of NDM-1-Encoding Plasmids in Latin American Clinical Isolates Reveals Insights into the Evolution of Multidrug Resistance. Genome Biol Evol 9:1725–1741
48. Plante I, Centron D, Roy PH (2003) An integron cassette encoding erythromycin esterase, ere(A), from Providencia stuartii. J Antimicrob Chemother 51:787–790
49. Barlow RS, Pemberton JM, Desmarchelier PM, Gobius KS (2004) Isolation and characterization of integron-containing bacteria without antibiotic selection. Antimicrob Agents Chemother 48:838–842
50. Barlow RS, Gobius KS (2006) Diverse class 2 integrons in bacteria from beef cattle sources. J Antimicrob Chemother 58:1133–1138

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.